1 citations
,
August 2025 in “Medicina” This review discusses the evolution and potential of non-invasive imaging techniques for diagnosing scalp diseases, highlighting their advantages and limitations compared to trichoscopy and scalp biopsy, the current diagnostic standards.
March 2025 in “JAAD reviews.” This review found that bimatoprost effectively treats chemotherapy-induced eyelash loss, known as milphosis, in cancer patients, as demonstrated in three small trials, but further research is needed due to limitations like small sample sizes and short follow-up periods.
May 2023 in “Dermatology and therapy” This study aims to provide a practical guide for managing common causes of madarosis, highlighting the need to identify underlying causes to ensure effective treatment for eyelash and eyebrow loss.
4 citations
,
March 2023 in “Current Oncology” This study reviews current methods and emerging approaches to prevent and treat chemotherapy-induced hair loss, reporting that evidence-based research is needed to validate effective strategies, which could enhance cancer patients’ quality of life and treatment compliance.
6 citations
,
October 2022 in “American journal of clinical dermatology” This review provides an updated overview of the symptomatology, diagnosis, trichoscopy findings, and treatment options for eyebrow and eyelash alopecia, but it reports no new experimental results.
4 citations
,
November 2021 in “Cancers” This paper reviews various causes of alopecia in cancer patients and highlights the importance of understanding these mechanisms for effective management, but reports no new findings.
4 citations
,
November 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.
17 citations
,
June 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This paper provides an overview of scalp cooling as an effective and safe intervention for preventing chemotherapy-induced alopecia, addressing its impact on cancer patients and survivors.
43 citations
,
March 2019 in “JAMA Dermatology” This study found that persistent chemotherapy-induced alopecia is often more severe and diffuse than alopecia from endocrine therapy, with both conditions negatively impacting patients' emotional wellbeing, and moderate to significant improvement was observed with dermatologic therapy.
38 citations
,
September 2017 in “Oncologist” This source reports that scalp cooling is currently the only safe and FDA-cleared method to potentially reduce chemotherapy-induced hair loss, with about a 50% chance of maintaining sufficient hair to avoid needing a wig.
